Opus Genetics, Inc.IRD
Price (close)
$4.87
Market cap
$405.2M
P/E
—
Revenue (TTM)
$9.9M
Net income
-$107.6M
Dividend yield
—
1-year total return
183.1%
Net margin
-1091.8%
Revenue growth
-36.1%
Debt / equity
—
What Opus Genetics, Inc. does.
Opus Genetics, Inc. (the “Company,” “Opus,” “we,” “us,” or “our”) is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent
blindness in patients with inherited retinal diseases (“IRDs”), and other types of therapies for additional ophthalmic disorders.
In April 2018, Ocuphire Pharma, Inc. merged with Ocularis Pharma, LLC, the original innovator of phentolamine mesylate ophthalmic solution.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $589,000 | $39.9M | $19.0M | $11.0M | $14.2M |
| Net income | -$24.6M | -$56.7M | $17.9M | -$10.0M | -$57.5M | -$49.6M |
| Free cash flow | -$6.8M | — | — | — | — | — |
More on IRD.
- Opus Genetics, Inc. summary
- Opus Genetics, Inc. financial statements
- Opus Genetics, Inc. key metrics
- Opus Genetics, Inc. health scores and style box
- Opus Genetics, Inc. earnings
- Opus Genetics, Inc. dividends
- Opus Genetics, Inc. valuation
- Opus Genetics, Inc. ownership and insiders
- Opus Genetics, Inc. peers
Figures from Opus Genetics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.